杭州晶华微电子股份有限公司 2023 年度董事会审计委员会履职情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》和《杭州晶华微电子股份有限公司章程》（以 下简称"《公司章程》"）等有关规定和要求，杭州晶华微电子股份有限公司（以 下简称"公司"）董事会审计委员会勤勉尽责、恪尽职守，认真履行审计监督职责。 现将公司董事会审计委员会 2023 年度履职情况报告如下： 一、董事会审计委员会基本情况 公司董事会审计委员会由 3 名委员组成。第一届董事会审计委员会委员为李 远鹏先生、王明琳先生和罗伟绍先生，主任委员由具有会计专业资格的李远鹏先 生担任。因第一届董事会任期届满，公司于 2023 年 12 月 8 日完成董事会换届选 举工作，并于同日召开第二届董事会第一次会议，会议选举产生公司第二届董事 会审计委员会委员：余景选先生、陈英骅先生和罗伟绍先生，主任委员由具有会 计专业资格的余景选先生担任。审计委员会各成员均具备能够胜任审计委员会工 作职责的专业知识和工作经验。 二、报告期内董 ...

证券代码：688130 证券简称：晶华微 公告编号：2024-016 杭州晶华微电子股份有限公司 关于购买董监高责任险的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步完善杭州晶华微电子股份有限公司（以下简称"公司"）风险管理体 系，降低公司运营风险，保障公司董事、监事及高级管理人员的权益和广大投资 者利益，同时促进公司董事、监事及高级管理人员充分行使权利、履行职责，根 据《中华人民共和国公司法》《上市公司治理准则》等规定，公司于 2024 年 4 月 25 日召开第二届董事会第四次会议和第二届监事会第二次会议，审议通过了《关 于购买董监高责任险的议案》，因该事项与公司全体董事、监事及高级管理人员 存在利害关系，因此全体董事、监事在审议该事项时回避表决，公司董事会、监 事会同意将该议案直接提交公司股东大会审议。现将有关事项公告如下： 二、监事会意见 2、被保险人：公司及公司全体董事、监事、高级管理人员（具体以保险合 同为准） 3、赔偿限额：不超过人民币 5,000 万元/年（具体以保险合同为准） 4、保险费预算： ...

杭州晶华微电子股份有限公司 2023 年度独立董事述职报告 （陈英骅） （二）独立性情况说明 作为公司的独立董事，本人未在公司担任除独立董事及董事会各相关专门委 员会成员以外的任何职务，也未在公司主要股东公司担任任何职务，与公司以及 主要股东之间不存在利害关系、重大业务往来或其他可能妨碍其进行独立客观判 断的关系，符合《上市公司独立董事管理办法》、《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要求。 二、独立董事年度履职概况 （一）出席董事会和股东大会情况 2023 年，公司共召开 12 次董事会会议和 3 次股东大会，本人在任职期内均 积极出席公司董事会会议和股东大会，具体情况如下： | | | | | 参加董事会情况 | | | 参加股东大 | | --- | --- | --- | --- | --- | --- | --- | --- | | 独立董事 | | | | | | | 会情况 | | 姓名 | 本年应参 | 亲自 | 以通讯 | 委托出 | 缺席 | 是否连续两 | 出席股东大 | | | 加董事会 | 出席 | 方式参 | 席次数 | 次数 ...

Financial Performance - In Q1 2024, the company reported a revenue of CNY 26,704,868.92, a decrease of 8.81% year-over-year[5] - The net profit attributable to shareholders was CNY -1,142,936.53, representing a decline of 138.57% compared to the same period last year[5] - Total operating revenue for Q1 2024 was CNY 26,704,868.92, a decrease of 8.6% compared to CNY 29,284,068.48 in Q1 2023[26] - Net profit for Q1 2024 was a loss of CNY 1,142,936.53, compared to a profit of CNY 2,963,461.60 in Q1 2023[27] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.02, down from CNY 0.04 in Q1 2023[28] - Total liabilities decreased to CNY 12,640,640.83 from CNY 22,921,993.42 year-over-year[24] Research and Development - The company's R&D investment totaled CNY 15,894,086.36, accounting for 59.52% of its revenue, an increase of 6.79 percentage points year-over-year[6] - Research and development expenses for Q1 2024 were CNY 15,894,086.36, slightly up from CNY 15,442,171.34 in Q1 2023[26] - The company is actively developing multiple new products, including various SoC chips and low-noise operational amplifiers, to enhance its market position[8] Cash Flow and Liquidity - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 761,254,104.72, a slight increase from RMB 757,373,393.82 on December 31, 2023[22] - The cash inflow from operating activities was $30,445,552.39, a significant increase from $12,755,089.71 in Q1 2023, representing an increase of approximately 138.8%[30] - The net cash outflow from operating activities in Q1 2024 was $11,306,272.29, an improvement compared to a net outflow of $18,636,533.46 in Q1 2023, indicating a reduction of about 39.5%[31] - Cash inflow from investment activities totaled $242,520,978.19 in Q1 2024, compared to $190,313,277.95 in Q1 2023, marking an increase of approximately 27.5%[31] - The net cash flow from investment activities was $19,692,912.19 in Q1 2024, a significant recovery from a net outflow of $110,898,577.25 in Q1 2023[31] - The total cash and cash equivalents at the end of Q1 2024 amounted to $761,254,104.72, up from $851,542,530.92 at the end of Q1 2023[32] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,282,483,120.23, a decrease of 0.85% from the end of the previous year[6] - Total assets as of the end of Q1 2024 were CNY 1,282,483,120.23, a slight decrease from CNY 1,293,517,949.53 at the end of Q1 2023[25] - Non-current assets totaled CNY 14,841,300.54, up from CNY 9,181,026.10 in Q1 2023[25] - The company reported trading financial assets of RMB 211,000,000.00, down from RMB 220,000,000.00, representing a decrease of approximately 4.1%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,778[14] - The top ten shareholders include Hai Tong Innovation Securities Investment Co., holding 615,600 shares, which is 0.92% of total shares[18] - There were no changes in the top ten shareholders due to the transfer of shares during the reporting period[18] Management and Strategy - The company appointed Mr. Feng Qin as the new Chief Financial Officer, effective immediately following the board meeting[19] - The company adjusted its sales strategy in response to increased market competition, resulting in a higher sales volume despite reduced revenue[7] - The strategic placement plan involved participation from core employees, indicating a commitment to align interests with shareholders[16] - The company has not disclosed any significant new product developments or market expansions during this reporting period[19] Operating Costs - Total operating costs increased to CNY 34,706,941.52, up 20.5% from CNY 28,835,601.50 in the same period last year[26] - The company experienced an increase in sales costs and management expenses, leading to a net profit of CNY 171,520 after excluding share-based payment expenses of CNY 2,858,100[7][8] - The company reported a significant increase in management expenses to CNY 7,330,577.52 from CNY 3,679,868.46 in the previous year[26] Financial Reporting - The company’s financial report is unaudited, which may affect the reliability of the financial data presented[21]

重要内容提示： 拟以资本公积向全体股东每 10 股转增 4 股，不派发现金红利，不送红股。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州晶华微电子股份有限公司 关于 2023 年度利润分配暨资本公积转增股本预案的公告 证券代码：688130 证券简称：晶华微 公告编号：2024-011 同时提请股东大会授权公司董事会及授权人士具体执行上述利润分配暨资本公 积转增股本预案，根据实施结果适时变更注册资本、修订《公司章程》相关条款并办 理相关工商登记变更手续。 本次利润分配暨资本公积转增股本预案尚需提交公司 2023 年年度股东大会审议。 二、公司履行的决策程序 1、董事会会议的召开、审议和表决情况 公司于 2024 年 4 月 25 日召开第二届董事会第四次会议，审议通过了《关于 2023 年度利润分配暨资本公积转增股本预案的议案》，本预案符合《公司章程》规定的利 润分配政策，董事会同意本次利润分配暨资本公积转增股本预案并同意提交公司 2023 年年度股东大会审议。 本次利润分配暨资本公积转增股本预案以实施权益分派股权登记 ...

Financial Performance - The company's operating revenue for 2023 was CNY 126,805,482.06, representing a 14.19% increase compared to CNY 111,043,287.25 in 2022[23]. - The net profit attributable to shareholders for 2023 was a loss of CNY 20,350,966.15, a decrease of 191.98% from a profit of CNY 22,125,087.12 in 2022[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 35,102,089.01, down 446.48% from CNY 10,131,134.01 in 2022[23]. - The net cash flow from operating activities increased by 132.90% to CNY 36,798,287.48 from CNY 15,800,100.50 in 2022[23]. - The total assets at the end of 2023 were CNY 1,293,517,949.53, a decrease of 3.94% from CNY 1,346,539,258.96 at the end of 2022[23]. - The net assets attributable to shareholders at the end of 2023 were CNY 1,270,595,956.11, down 3.03% from CNY 1,310,290,477.98 at the end of 2022[23]. - The company's basic and diluted earnings per share fell by 179.49% to -0.31 yuan per share, while the earnings per share excluding non-recurring gains and losses dropped by 394.44% to -0.53 yuan[26]. - The weighted average return on equity decreased by 4.48 percentage points to -1.57%[24]. Shareholder Actions - The company implemented a share buyback program in 2023, with a total repurchase amount of ¥18,519,427.75[5]. - The profit distribution plan for 2023 includes a capital reserve increase of 4 shares for every 10 shares held, resulting in a total increase of 26,414,389 shares[6]. - After the capital increase, the total share capital will rise to 92,974,389 shares[6]. - As of March 31, 2024, the adjusted total share capital, after accounting for repurchased shares, will be 66,035,973 shares[6]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - There are no special arrangements for corporate governance applicable to the company[8]. - The company has not violated any decision-making procedures regarding external guarantees[10]. - The company held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[141]. - The board of directors convened 12 meetings during the reporting period, maintaining compliance with legal and regulatory requirements[142]. - The supervisory board held seven meetings, ensuring diligent oversight of the company's operations and protecting shareholder interests[142]. Research and Development - The company is committed to ongoing research and development of new technologies to maintain competitive advantage in the market[22]. - Research and development expenses accounted for 62.12% of operating revenue, an increase of 19.02 percentage points compared to the previous year[24]. - The company’s R&D investment increased by 64.58% year-on-year, totaling approximately ¥78.77 million, compared to ¥47.86 million in the previous year[66]. - The company has increased its R&D personnel from 89 to 136, representing a growth rate of 52.8%[77]. - R&D personnel now account for 71.20% of the total workforce, up from 66.42% in the previous period[77]. - The company has applied for 11 new invention patents and received approval for 3 during the reporting period, bringing the total approved invention patents to 22[64]. Market and Industry Trends - The company is focusing on expanding its market presence and enhancing its product offerings in the semiconductor industry[22]. - The global semiconductor market is projected to grow significantly, with an estimated size of $673.1 billion in 2024 and a compound annual growth rate (CAGR) of 8.8% from 2023 to 2032, potentially reaching $1.3 trillion by 2032[49]. - The home medical device market in China is expected to reach a scale of 350 billion yuan by 2025, driven by increasing health awareness and an aging population[54]. - The integrated circuit market in China is expected to grow from RMB 892.8 billion in 2020 to RMB 1,893.2 billion by 2025, representing a compound annual growth rate (CAGR) of 16.2%[130]. Product Development - The company has developed a range of proprietary products, including high-precision ADC signal processing SoC technology, maintaining a leading position in infrared temperature measurement and digital multimeter applications[52]. - The company launched several new products, including high-performance SoC chips for blood pressure monitors and temperature sensors, contributing to revenue growth[36]. - The company is developing a series of battery management chips and general-purpose signal chain chips to create new profit growth points[38]. - The company is expanding its product line to include advanced medical electronics, with projects focused on ECG and EEG measurement applications[72]. Risk Management - The company has outlined potential risks in its annual report, which investors should pay attention to[4]. - The company faces risks from intensified market competition, with competitors including international giants and domestic firms, which may lead to price declines and reduced industry profits[90]. - Continuous R&D investment and technology upgrades are crucial for maintaining competitive advantages in the rapidly evolving integrated circuit design industry[86]. Employee and Talent Management - A stock incentive plan was implemented, granting 1.2675 million restricted shares to enhance employee motivation and team cohesion[40]. - The company has implemented a performance bonus and stock incentive plan to motivate employees and align their interests with the company's growth[174]. - The total remuneration for core technical personnel at the end of the reporting period was CNY 406.52 million[159]. - The company emphasizes talent acquisition and development, aiming to strengthen team cohesion and employee motivation through effective incentive mechanisms[136]. Compliance and Regulatory Issues - The company received regulatory warnings from the Shanghai Stock Exchange and the China Securities Regulatory Commission in 2023 due to compliance issues[162]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[143]. - The company has established a governance structure that clearly defines the roles and responsibilities of its decision-making and supervisory bodies[140].

公司代码：688130 公司简称：晶华微 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程 度降低，根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 1. 公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 □是 √否 2. 财务报告内部控制评价结论 √有效 □无效 杭州晶华微电子股份有限公司 2023 年度内部控制评价报告 杭州晶华微电子股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制 ...

证券代码：688130 证券简称：晶华微 公告编号：2024-015 杭州晶华微电子股份有限公司 关于向银行申请综合授信额度的公告 杭州晶华微电子股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 第二届董事会第四次会议和第二届监事会第二次会议，审议通过了《关于向银行 申请综合授信额度的议案》，该事项在公司董事会审批权限范围内，无需提交公 司股东大会审议。现将相关情况公告如下： 为提高企业资金运营能力，根据公司整体资金预算安排、经营战略及总体发 展计划，公司拟向合作银行申请总额不超过人民币 3 亿元（含本数）的综合授信 额度，授信业务包括但不限于短期流动资金贷款、项目贷款、中长期借款、银行 承兑汇票、保函、票据贴现等，具体授信业务品种、额度和期限，以各家银行最 终核定为准。 该授信有效期为自本次董事会审议通过之日起至下一年度董事会召开之日 止。在授信期限内，授信额度可循环使用，可以在不同银行间进行调整，单笔融 资可不再上报董事会或股东大会审议。以上授信额度不等于公司的实际融资金额， 实际融资金额应在授信额度内，并以公司与合作银行实际发生的融资金额为准， 具体融资金额及品种等将视公司业务发展 ...

海通证券股份有限公司 关于杭州晶华微电子股份有限公司 使用部分超募资金永久补充流动资金的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为杭州晶华 微电子股份有限公司（以下简称"晶华微"或"公司"）首次公开发行股票并上市持 续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续 督导》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 有关规定，对公司使用部分超募资金永久补充流动资金事项进行了核查，具体情 况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意杭州晶华微电子股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕1203 号），公司首次向 社会公开发行人民币普通股 1,664 万股，每股发行价格为人民币 62.98 元，募集 资金总额为 1,047,987,200.00 元；减除发行费用人民币 127,450,183.35 元后，募 集资金净额为 920,537,016.65 元。上述募集资金已全部到位，经天健会计师事务 所（特殊普通合 ...